L-asparaginase and venous thromboembolism in acute lymphocytic leukemia

Gaurav Goyal, Vijaya Raj Bhatt

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


The occurrence of venous thromboembolism (VTE) in acute lymphocytic leukemia patients receiving L-asparaginase therapy may cause significant morbidity, neurological sequela and possibly worse outcomes. The prophylactic use of antithrombin infusion (to keep antithrombin activity >60%) or low molecular weight heparin (LMWH) may reduce the risk of VTE. The decision to continue L-asparaginase therapy after the development of VTE should be based on anticipated benefits, severity of VTE and the ability to continue therapeutic anticoagulation. In patients receiving asparaginase rechallenge, the use of therapeutic LMWH, monitoring of anti-Xa level and antithrombin level are important. Novel oral anticoagulants are not dependent on antithrombin level, hence offer theoretical advantages over LMWH for the prevention and therapy of asparaginase-related VTE.

Original languageEnglish (US)
Pages (from-to)2459-2470
Number of pages12
JournalFuture Oncology
Issue number17
StatePublished - Sep 1 2015


  • acute lymphocytic leukemia
  • asparaginase
  • thrombosis
  • venous thromboembolism

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'L-asparaginase and venous thromboembolism in acute lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this